$PFE
Pfizer Inc. · NYSE · Healthcare
- Market cap
- 162.16B
- Volume
- 23.53M
- P/E
- 37.43
- Day range
- 28.38 – 28.69
- 52w range
- 23.58 – 29.21
- Analyst target
- 28.61
AI Summary
Generating a unique summary for PFE…
AI-generated for information only — not investment advice.
Share this ticker
$PFE -1.25% at 28.45 Bill Ackman and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/PFE
Company summary
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Institutional ownership
Institutions hold 69.25% · insiders 0.10% · 3,645 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 529.67M | $15.07B | 9.29% | 2026-06-30 |
| Vanguard Capital Management LLC | 372.15M | $10.59B | 6.53% | 2026-06-30 |
| State Street Corporation | 307.09M | $8.74B | 5.39% | 2026-06-30 |
| Geode Capital Management, LLC | 135.28M | $3.85B | 2.37% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 119.24M | $3.39B | 2.09% | 2026-06-30 |
| Fisher Asset Management, LLC | 109.07M | $3.10B | 1.91% | 2026-06-30 |
| Morgan Stanley | 96.35M | $2.74B | 1.69% | 2026-06-30 |
| NORGES BANK | 61.51M | $1.75B | 1.08% | 2026-06-30 |
| Northern Trust Corporation | 59.08M | $1.68B | 1.04% | 2026-06-30 |
| Bank Of New York Mellon Corporation | 57.88M | $1.65B | 1.02% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| BOURLA ALBERT | Chief Executive Officer | Purchase at price 26.34 per share. | 38.0K | 2026-08-12 |
| DAMICO JENNIFER B. | Officer | Sale at price 25.40 per share. | 3.3K | 2026-08-05 |
| BLAYLOCK RONALD E | Director | Purchase at price 25.46 per share. | 39.2K | 2026-08-05 |
| BUCKLEY MORTIMER J. | Director | Purchase at price 25.52 per share. | 37.6K | 2026-08-05 |
| DAMICO JENNIFER B. | Officer | Sale at price 25.70 per share. | 2.0K | 2026-06-09 |
| DAMICO JENNIFER B. | Officer | Stock Award(Grant) at price 0.00 per share. | 21.7K | 2026-03-03 |
| BOSHOFF CHRISTOFFEL | Officer | Stock Award(Grant) at price 0.00 per share. | 13.4K | 2026-02-25 |
| BOURLA ALBERT | Chief Executive Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 491.6K | 2026-02-25 |
| SAHNI PAYAL | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 56.9K | 2026-02-25 |
| MCDERMOTT MICHAEL | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 37.9K | 2026-02-25 |
| DAMICO JENNIFER B. | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 17.6K | 2026-02-25 |
| LANKLER DOUGLAS M | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 122.9K | 2026-02-25 |
Analyst ratings
Consensus score 2.46 (1 = strong buy, 5 = sell) · mean target 28.61
- GuggenheimBuymain2026-08-07
- BMO CapitalOutperformmain2026-07-13
- GuggenheimBuymain2026-07-13
- B of A SecuritiesNeutralmain2026-07-10
- JP MorganNeutralmain2026-07-08
- Cantor FitzgeraldNeutralreit2026-07-06
- HSBCHolddown2026-07-06
- RBC CapitalSector Performup2026-06-10
- CitigroupNeutralmain2026-04-29
- RBC CapitalUnderperformreit2026-04-20
Earnings
Next report: 2026-11-03
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 0.87 | 0.63 | 0.24 |
| 4Q2025 | 0.66 | 0.57 | 0.09 |
| 1Q2026 | 0.75 | 0.72 | 0.03 |
| 2Q2026 | 0.77 | 0.68 | 0.09 |
SEC filings
- N-PXAnnual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX2026-08-31Open
- 8-KCorporate Changes & Voting Matters2026-08-04Open
- 8-KCorporate Changes & Voting Matters2026-06-18Open
- 11-KAnnual report of employee stock purchase2026-06-16Open
- S-8Offering Registrations2026-05-05Open
- 8-KCorporate Changes & Voting Matters2026-04-27Open
- ARSAnnual Report to Shareholders2026-03-12Open
- 10-KPeriodic Financial Reports2026-02-26Open
- 8-KCorporate Changes & Voting Matters2026-02-03Open
- 8-KCorporate Changes & Voting Matters2025-12-16Open
Latest PFE news
- Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.
Mon, 07 Sep 2026 17:00:45 +0000
- This Is What I'd Do With Pfizer Stock Right Now
The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.
Mon, 07 Sep 2026 15:50:01 +0000
- Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
Mon, 07 Sep 2026 11:02:00 +0000
- AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Fri, 04 Sep 2026 18:50:01 +0000
- Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
Fri, 04 Sep 2026 13:42:11 +0000
- Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
Fri, 04 Sep 2026 09:00:00 +0000
- Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value
Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh product news in the background, investors are weighing how much of the recent optimism is already reflected in the share price. The 25.6% 1 year return suggests sentiment toward Pfizer has improved meaningfully, which raises the bar for further upside driven purely by valuation. Approval of Pfizer...
Fri, 04 Sep 2026 01:07:38 +0000
- Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check
Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...
Fri, 04 Sep 2026 00:22:05 +0000